TONGHUA DONGBAO PHARMACEUTICAL CO., LTD. Funds and ETFs Tonghua Dongbao Pharmaceutical Co., Ltd.
Equities
600867
CNE000000H87
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.59 CNY | +4.03% |
|
+5.58% | -2.22% |
| Apr. 26 | Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 29 | Dongbao Pharma's 2023 Profit Drops 26% | MT |
ETFs positioned on Tonghua Dongbao Pharmaceutical Co., Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.33% | 12 M€ | -16.71% | - | |
| 0.28% | 2 M€ | -16.59% | - | |
| 0.00% | 34 M€ | +2.14% | - |
TONGHUA DONGBAO PHARMACEUTICAL CO., LTD. is a China-based company, principally engaged in the research and development, manufacture and distribution of pharmaceuticals. The Company provides biological products, traditional Chinese medicines and chemical supplements, applied in the treatment of diabetes and cardiovascular and cerebrovascular diseases, among others. The Company's main products portfolio consists of recombinant human insulin bulk drugs and injections, zhennaoning capsules, among others. The Company also provides medical instruments, plastic-steel windows and profiles, and operates property business. The Company distributes its products within domestic markets and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-20
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
10.59
CNY
Average target price
15.27
CNY
Spread / Average Target
+44.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.22% | 2.9B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- 600867 Stock
- Funds and ETFs Tonghua Dongbao Pharmaceutical Co., Ltd.
